TNF and neutropenia: Outside the context of oncology, biotherapies have been reported as being the cause of early and transient Grade 1–2 neutropenia in 10–15% of the treated patients, often with TNF-α inhibitors [16,19,20,21,22,23,24], tocilizumab [25,26,27], rituximab [14,27,28,29,30,31,32,33,34,35,36], and alemtuzumab [15,37,38,39,40,41,42].